Infections in Pediatric Transplant Recipients

  • Aspasia Katragkou
  • Lucy O’Connor
  • Emmanuel Roilides
  • Thomas J. WalshEmail author


Infections are major complications in pediatric patients undergoing hematopoietic stem cell or solid organ transplantation. They also represent the most significant barrier to short- and long-term survival of the transplanted allograft. The achievements and advances during the past 30 years have resulted in remarkably improved outcome for pediatric patients undergoing transplantation. These advances in pediatric infectious disease supportive care have contributed substantially to the patients’ well-being and improved survival, alike. The immune defects and the possible etiologic agents for infection vary with the time elapsed since transplantation, a formal timetable for infectious complications after hematopoietic stem cell and solid organ transplantation forms the bases for an organized approach to assess a relevant differential diagnosis, treatment and management plan for these complex and severely immunosuppressed young transplant recipients. In this chapter a comprehensive review on epidemiology, clinical manifestations, and strategies for managing infectious diseases in pediatric transplant recipients is provided.


Pediatric transplant Bacterial infections Fungal infections Viral infections Hematopoietic stem cell transplantation Sold organ transplantation 


  1. 1.
    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, European Blood and Marrow Transplant Group, American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Disease Canada, Centers for Disease Control and Prevention, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Fishman JA. Infection in organ transplantation. Am J Transplant. 2017;17:856–79.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Fonseca-Aten M, Michaels MG. Infections in pediatric solid organ transplant recipients. Semin Pediatr Surg. 2006;15:153–61.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Sung L, Phillips R, Lehrnbecher T. Time for paediatric febrile neutropenia guidelines – children are not little adults. Eur J Cancer. 2011;47:811–3.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99:580–8.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis. 1994;18:273–81; quiz 282–274.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Parkman R, Weinberg KI. Immunological reconstitution following bone marrow transplantation. Immunol Rev. 1997;157:73–8.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Infectious complications in pediatric cancer patients. In: Pizzo A, Poplack DG, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2015.Google Scholar
  9. 9.
    Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis. 2004;39(Suppl 1):S38–43.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant. 2000;26:999–1004.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 1997;19:801–8.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    O’Donnell MR, Schmidt GM, Tegtmeier BR, Faucett C, Fahey JL, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol. 1994;12:827–34.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38:1237–42.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006;117:e711–6.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore). 1993;72:78–89.CrossRefGoogle Scholar
  16. 16.
    Fisher BT, Alexander S, Dvorak CC, Zaoutis TE, Zerr DM, et al. Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. Pediatr Blood Cancer. 2012;59:11–5.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Wasserman R, August CS, Plotkin SA. Viral infections in pediatric bone marrow transplant patients. Pediatr Infect Dis J. 1988;7:109–15.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Hale GA, Heslop HE, Krance RA, Brenner MA, Jayawardene D, et al. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999;23:277–82.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med. 1985;312:529–33.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    van Tol MJ, Claas EC, Heemskerk B, Veltrop-Duits LA, de Brouwer CS, et al. Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. Bone Marrow Transplant. 2005;35(Suppl 1):S73–6.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Storek J. Immunological reconstitution after hematopoietic cell transplantation – its relation to the contents of the graft. Expert Opin Biol Ther. 2008;8:583–97.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Weber C, Schaper J, Tibussek D, Adams O, Mackenzie CR, et al. Diagnostic and therapeutic implications of neurological complications following paediatric haematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:253–9.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant. 1994;13:549–57.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Mele A, Paterson PJ, Prentice HG, Leoni P, Kibbler CC. Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant. 2002;29:691–8.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Walker M, Zunt JR. Parasitic central nervous system infections in immunocompromised hosts. Clin Infect Dis. 2005;40:1005–15.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Wingard JR, Piantadosi S, Burns WH, Zahurak ML, Santos GW, et al. Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. Rev Infect Dis. 1990;12(Suppl 7):S793–804.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003;102:4255–60.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185:273–82.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, et al. Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol. 2004;65:416–22.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109:777–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109:783–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Walls T, Shankar AG, Shingadia D. Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. Lancet Infect Dis. 2003;3:79–86.PubMedCrossRefGoogle Scholar
  33. 33.
    Hierholzer JC. Adenoviruses in the immunocompromised host. Clin Microbiol Rev. 1992;5:262–74.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Runde V, Ross S, Trenschel R, Lagemann E, Basu O, et al. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant. 2001;28:51–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Matthes-Martin S, Feuchtinger T, Shaw PJ, Engelhard D, Hirsch HH, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14:555–63.PubMedCrossRefGoogle Scholar
  36. 36.
    Leung TF, Chik KW, Li CK, Lai H, Shing MM, et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant. 2000;25:167–72.PubMedCrossRefGoogle Scholar
  37. 37.
    Maltezou HC, Kafetzis DA, Abisaid D, Mantzouranis EC, Chan KW, et al. Viral infections in children undergoing hematopoietic stem cell transplant. Pediatr Infect Dis J. 2000;19:307–12.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Rubin RH, Ikonen T, Gummert JF, Morris RE. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis. 1999;1:29–39.PubMedCrossRefGoogle Scholar
  39. 39.
    Marty FM, Rubin RH. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int. 2006;19:2–11.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Rubin RH, Marty FM. Principles of antimicrobial therapy in the transplant patient. Transpl Infect Dis. 2004;6:97–100.PubMedCrossRefGoogle Scholar
  41. 41.
    Rubin RH. Importance of CMV in the transplant population. Transpl Infect Dis. 1999;1(Suppl 1):3–7.PubMedGoogle Scholar
  42. 42.
    Gottesdiener KM. Transplanted infections: donor-to-host transmission with the allograft. Ann Intern Med. 1989;110:1001–16.PubMedCrossRefGoogle Scholar
  43. 43.
    Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348:2196–203.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. 2005;352:1103–11.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601–14.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Allen U, Green M. Prevention and treatment of infectious complications after solid organ transplantation in children. Pediatr Clin N Am. 2010;57:459–79.CrossRefGoogle Scholar
  47. 47.
    Keough WL, Michaels MG. Infectious complications in pediatric solid organ transplantation. Pediatr Clin N Am. 2003;50:1451–69.CrossRefGoogle Scholar
  48. 48.
    Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323–32.PubMedCrossRefGoogle Scholar
  49. 49.
    Shi J, Wu Y, Cai M, Shang S. Rapid diagnosis of herpetic encephalitis in children by PCR-microarray technology for simultaneous detection of seven human herpes viruses. Eur J Pediatr. 2010;169:421–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Schloss L, Falk KI, Skoog E, Brytting M, Linde A, et al. Monitoring of herpes simplex virus DNA types 1 and 2 viral load in cerebrospinal fluid by real-time PCR in patients with herpes simplex encephalitis. J Med Virol. 2009;81:1432–7.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Wada K, Mizoguchi S, Ito Y, Kawada J, Yamauchi Y, et al. Multiplex real-time PCR for the simultaneous detection of herpes simplex virus, human herpesvirus 6, and human herpesvirus 7. Microbiol Immunol. 2009;53:22–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Strick LB, Wald A. Diagnostics for herpes simplex virus: is PCR the new gold standard? Mol Diagn Ther. 2006;10:17–28.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Schiff D, Rosenblum MK. Herpes simplex encephalitis (HSE) and the immunocompromised: a clinical and autopsy study of HSE in the settings of cancer and human immunodeficiency virus-type 1 infection. Hum Pathol. 1998;29:215–22.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Miyashita N, Saito A, Kohno S, Yamaguchi K, Watanabe A, et al. Multiplex PCR for the simultaneous detection of Chlamydia pneumoniae, Mycoplasma pneumoniae and Legionella pneumophila in community-acquired pneumonia. Respir Med. 2004;98:542–50.PubMedCrossRefGoogle Scholar
  55. 55.
    Maltezou HC, La-Scola B, Astra H, Constantopoulou I, Vlahou V, et al. Mycoplasma pneumoniae and Legionella pneumophila in community-acquired lower respiratory tract infections among hospitalized children: diagnosis by real time PCR. Scand J Infect Dis. 2004;36:639–42.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Heussel CP, Kauczor HU, Heussel GE, Fischer B, Begrich M, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol. 1999;17:796–805.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Kim MJ, Lee KS, Kim J, Jung KJ, Lee HG, et al. Crescent sign in invasive pulmonary aspergillosis: frequency and related CT and clinical factors. J Comput Assist Tomogr. 2001;25:305–10.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Milito MA, Kontoyiannis DP, Lewis RE, Liu P, Mawlawi OR, et al. Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis. Med Mycol. 2010;48:817–23.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373–9.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Bergen GA, Shelhamer JH. Pulmonary infiltrates in the cancer patient. New approaches to an old problem. Infect Dis Clin N Am. 1996;10:297–325.CrossRefGoogle Scholar
  61. 61.
    Baker C. Serial Aspergillus antigen monitoring in pediatric bone marrow transplant patients. J Pediatr Oncol Nurs. 2006;23:300–4.PubMedCrossRefGoogle Scholar
  62. 62.
    Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004;190:641–9.CrossRefGoogle Scholar
  63. 63.
    Boutboul F, Alberti C, Leblanc T, Sulahian A, Gluckman E, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis. 2002;34:939–43.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis. 2002;186:1297–306.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7–14.PubMedCrossRefGoogle Scholar
  66. 66.
    Giamarellou H, Antoniadou A. Infectious complications of febrile leukopenia. Infect Dis Clin N Am. 2001;15:457–82.CrossRefGoogle Scholar
  67. 67.
    Klastersky J. Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer. 1993;29A(Suppl 1):S6–10.PubMedCrossRefGoogle Scholar
  68. 68.
    Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427–38.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061–5.PubMedCrossRefGoogle Scholar
  70. 70.
    Schimpff SC, Gaya H, Klastersky J, Tattersall MH, Zinner SH. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis. 1978;137:14–29.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Walsh TJ, Schimpff SC. Antibiotic combinations for the empiric treatment of the febrile neutropenic patient. Schweiz Med Wochenschr. 1983;14:58–63.Google Scholar
  72. 72.
    Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101–11.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Walsh TJ, Lee J, Lecciones J, Rubin M, Butler K, et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis. 1991;13:496–503.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764–71.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–402.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135:412–22.PubMedCrossRefGoogle Scholar
  77. 77.
    Doebbeling BN, Stanley GL, Sheetz CT, Pfaller MA, Houston AK, et al. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med. 1992;327:88–93.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Remington JS, Schimpff SC. Occasional notes. Please don’t eat the salads. N Engl J Med. 1981;304:433–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Pizzo PA, Purvis DS, Waters C. Microbiological evaluation of food items. For patients undergoing gastrointestinal decontamination and protected isolation. J Am Diet Assoc. 1982;81:272–9.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Mahfouz TH, et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis. 2002;35:E86–8.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol. 1989;5:131–42.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Hayes-Lattin B, Leis JF, Maziarz RT. Isolation in the allogeneic transplant environment: how protective is it? Bone Marrow Transplant. 2005;36:373–81.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Fischer SA, Lu K. Screening of donor and recipient in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):9–21.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med. 1987;106:7–11.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Schmeiser T, Kurrle E, Arnold R, Wiesneth M, Bunjes D, et al. Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation. Scand J Infect Dis. 1988;20:625–31.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–51.CrossRefGoogle Scholar
  87. 87.
    Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–52.CrossRefGoogle Scholar
  88. 88.
    Walsh TJ, Hiemenz J, Pizzo PA. Evolving risk factors for invasive fungal infections – all neutropenic patients are not the same. Clin Infect Dis. 1994;18:793–8.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–16.CrossRefGoogle Scholar
  90. 90.
    Saral R, Ambinder RF, Burns WH, Angelopulos CM, Griffin DE, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med. 1983;99:773–6.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med. 1982;73:229–35.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984;100:823–8.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988;318:70–5.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Perren TJ, Powles RL, Easton D, Stolle K, Selby PJ. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med. 1988;85:99–101.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Erlich KS, Jacobson MA, Koehler JE, Follansbee SE, Drennan DP, et al. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann Intern Med. 1989;110:710–3.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005–11.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601–7.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627–32.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177–88.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    American Academy of Pediatrics. Active immunizations. In: Pickering LK, editor. Red book: 2003 report of the committee on infectious diseases. 29th ed. Elk Grove Village: American Academy of Pediatrics; 2012. p. 83–6.Google Scholar
  101. 101.
    Sullivan KM, Dykewicz CA, Longworth DL, Boeckh M, Baden LR, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematol Am Soc Hematol Educ Program. 2001;1:392–421.CrossRefGoogle Scholar
  102. 102.
    Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000;49(RR-10):1–125, CE1–7.; Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol. 1995;13:1328–35.
  103. 103.
    Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353–7.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol. 1995;13:1323–7.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:949–54.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Michelow IC, McCracken GH. Antibacterial therapeutic agents. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, editors. Feigin and Cherry’s textbook of pediatric infectious diseases, vol. 2. Philadelphia: Saunders Elsevier; 2009. p. 3178–227.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Aspasia Katragkou
    • 1
    • 2
    • 3
  • Lucy O’Connor
    • 1
    • 4
  • Emmanuel Roilides
    • 5
  • Thomas J. Walsh
    • 1
    • 6
    • 7
    • 8
    Email author
  1. 1.Transplantation-Oncology Infectious Diseases Program, New York-Presbyterian/Weill Cornell Medical CenterNew YorkUSA
  2. 2.3rd Department of PediatricsAristotle University, Hippokration HospitalThessalonikiGreece
  3. 3.Nationwide Children’s Hospital, Department of Pediatric Infectious DiseasesColumbusUSA
  4. 4.University of Manchester School of MedicineManchesterUK
  5. 5.3rd Department of PediatricsHippokration Hospital, School of Health Sciences, Aristotle University of ThessalonikiThessalonikiGreece
  6. 6.Department of PediatricsNew York-Presbyterian/Weill Cornell Medical CenterNew YorkUSA
  7. 7.Department of Microbiology and ImmunologyNew York-Presbyterian/Weill Cornell Medical CenterNew YorkUSA
  8. 8.Transplant Infectious Diseases Program, Division of Infectious DiseasesIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations